Komori
TAUNS Laboratories (197A) · RiskFirst stated

Risks of funding constraints, refinancing and rising funding costs

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Liquidity and Cash Flow Management RiskA theme 266 companies write about · 262 as a headwind · 4 as a tailwind

12 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 267 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「Disruptions in financial markets or changes in the lending policies of financial institutions could constrain our ability to raise funds, increase funding costs, and affect our business and performance.」

    Separate from interest-rate and financial covenant risks, the company disclosed for the first time funding and liquidity risk as a standalone item, including the balance between short- and long-term funding, refinancing, and optimization of working capital.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks of funding constraints, refinancing and rising funding costs | TAUNS Laboratories,Inc. (197A) | Komori